Genitourinary Cancers Steering Committee

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

The Genitourinary Steering Committee (GUSC) was established in 2008.

Mission Statement

The GUSC functions to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in genitourinary cancer clinical research by addressing the design and prioritization of phase 3 trials and large phase 2 studies.

Roster of Genitourinary Steering Committee (GUSC) members


2015 Genitourinary Steering Committee Strategic Priorities

Task Forces

  • Prostate Cancer: Adam Dicker, M.D., Daniel Lin, M.D., and Charles J. Ryan, M.D. -  Co-chairs
  • Bladder Cancer: Dean Bajorin, M.D., Colin Dinney, M.D., and Jason A. Efstathiou, M.D., Ph.D. -  Co-chairs
  • Renal Cancer: Janice Dutcher, M.D., Michael Jewett, M.D., and Sabina Signoretti, M.D. -  Co-chairs

GUSC Activities

Clinical Trials Planning Meetings (CTPMs)

  • Novel Therapeutics for Non-Muscle Invasive Bladder Cancer – March 2015
  • Advanced Renal Cell Cancer – February 2013
  • National Cancer Institute Prostate Cancer Genetics Workshop – November 2010

Clinical Trials

The following are clinical trials that were approved at the concept stage by the Steering Committee:

Trial ID NCT ID Trial Title
RTOG-0815 NCT00936390 A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
CALGB-90802 NCT01198158 Randomized Phase III Trial Comparing Everolimus Plus Placebo versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors
ECOG-2810 NCT01575548 Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Subjects with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastasectomy

Find all NCI-sponsored clinical trials.

CCCT Contact: Abdul Tawab-Amiri, Ph.D.